〓痒性皮膚疾患に対するエバスチン (エバステル^【○!R】) の有効性と安全性の検討 : 追加投与による評価  [in Japanese] Efficacy and Safety of Ebastine (EBASTEL^【○!R】) for Pruritic Skin Disease : Evaluation of High-dose Administration  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

第二世代抗ヒスタミン薬であるエバスチン(エバステル<SUP>®</SUP>)のそう痒性皮膚疾患に対する有用性について, エバスチン10mg/日投与の効果不十分例に対し追加投与(20mg/日投与)した場合の有効性および安全性を検討した。そう痒性皮膚疾患の新患で未治療例および他の抗ヒスタミン薬の効果不十分例115例を対象に, エバスチン10mg/日を2週間投与し, 効果不十分の場合は20mg/日をさらに2週間投与した。20mg/日投与が有効な場合は10mg/日に減量し継続, 効果不十分の場合は20mg/日を継続し, いずれも2週間投与した。その結果, エバスチン10mg/日を2週間投与後, 再来院のあった99例中, 有効例は61例, 効果不十分例は38例であった。効果不十分例のうち脱落1例を除く37例にエバスチン20mg/日をさらに2週間投与したところ, 有効例は11例であった。これらの症例では皮膚症状とかゆみ(VAS値)の有意な改善が得られ, 10mg/日に減量後も維持された。エバスチンの追加投与に伴う新たな有害事象の発現はなかった。以上の結果から, エバスチンはそう痒性皮膚疾患に有効な薬剤であることが確認され, さらに10mg/日投与で効果不十分の場合は20mg/日投与に増量することでさらなる改善効果が期待できることが確認された。

To assess the usefulness of a second-generation antihistamine, ebastine (EBASTEL<SUP>®</SUP>), for pruritic skin disease, we investigated the efficacy and safety of ebastine administration at 20 mg/day to patients who showed an insufficient response at 10 mg/day. A total of 115 patients with pruritic skin disease, including new patients and those with an insufficient response to other antihistamines, were treated with 10 mg/day of ebastine for two weeks. Those in whom the drug showed insufficient efficacy then received treatment at 20 mg/day for another two weeks. If the patient showed a good response at 20 mg/day, the dose was decreased to 10 mg/day again, while it was maintained at 20 mg/day if the response was inadequate, followed by a further two-week treatment period in both groups of patients. As a result, of 99 patients who completed the first two-week treatment period with 10 mg/day of ebastine, 61 showed a good response and 38 did not. Thirty-seven of the 38 patients with an inadequate response (except for 1 dropout), then received two weeks of treatment at 20 mg/day, after which 11 showed a good response. In these 11 patients, significant improvement of skin symptoms and improvement of itching (VAS) was maintained. High-dose administration of ebastine caused no new adverse events. The above findings indicate that ebastine is an effective drug for pruritic skin disease and that increasing the dose to 20 mg/day in patients with poor response to 10 mg/day can achieve a better effect.

Journal

  • Nishi Nihon Hifuka

    Nishi Nihon Hifuka 71(6), 609-615, 2009-12-01

    Western Division of Japanese Dermatological Association

References:  10

Codes

  • NII Article ID (NAID)
    10026321817
  • NII NACSIS-CAT ID (NCID)
    AN00183881
  • Text Lang
    JPN
  • Article Type
    ART
  • ISSN
    03869784
  • NDL Article ID
    10525576
  • NDL Source Classification
    ZS39(科学技術--医学--皮膚科学・泌尿器科学)
  • NDL Call No.
    Z19-69
  • Data Source
    CJP  NDL  J-STAGE 
Page Top